FATE THERAPEUTICS INC Operating Lease Liability
FATE THERAPEUTICS INC (FATE) had Operating Lease Liability of $75.67 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-13
- 2026-06-30: Operating Lease, Liability $75.67M.
- 2026-03-31: Operating Lease, Liability $76.78M.
- 2025-12-31: Operating Lease, Liability $77.85M.
- 2025-09-30: Operating Lease, Liability $79.25M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $75.67M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $76.78M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $77.85M 10-K · filed 2026-02-26 |
| 2025-09-30 | $79.25M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $81.33M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $83.33M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $85.27M 10-K · filed 2025-03-05 |
| 2024-09-30 | $98.98M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $100.56M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $102.07M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $103.54M 10-K · filed 2024-02-26 |
| 2023-09-30 | $104.95M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $106.35M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $107.61M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $109.34M 10-K · filed 2023-02-28 |
| 2022-09-30 | $110.92M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $112.30M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $113.52M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $114.82M 10-K · filed 2022-02-28 |
| 2021-09-30 | $109.06M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $110.47M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $110.92M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $97.30M 10-K · filed 2021-02-24 |
| 2020-09-30 | $85.49M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $81.04M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $75.73M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $26.93M 10-K · filed 2020-03-02 |
| 2019-09-30 | $27.30M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $27.67M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $27.72M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |